BMRNBioMarin Pharmaceutical Inc.
$54.80+0.81% 1Y
$54.80
$49.6752 weeks$70.23
BMRN in its own filings
Nothing in BMRN's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
570
Events found in the filings · across 2,740 filings · the record starts in 1999
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 6, 2026
Most recent filing · Form 8-K
- Record starts
- Sep 7, 1999
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Jan 11, 2027
- SEC comment-letter activity48 occurrences
- 2025-06-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis)Material agreement entered · Form 8-K
- Sep 15, 2026On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome.Other event · Form 8-K
- Sep 14, 2026On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date)Director or officer change · Form 8-K
- Sep 1, 2026As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), entered into a Share Purchase Agreement (the “Purchase Agreement”) with (i) Alesta Therapeutics B.V., a Dutch …Other event · Form 8-K
- Aug 31, 2026On August 30, 2026 (the “Effective Date”), BioMarin Pharmaceutical Inc. (“BioMarin”) entered into a binding term sheet (the “Term Sheet”) with Ascendis Pharma A/S (“Ascendis”) that sets forth the terms and conditions for a global settlement and license agreement (the “Agreement”) that resolves all pending proceedings …Material agreement entered · Form 8-K
- Aug 18, 2026On August 17, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), entered into a Share Purchase Agreement (the “Purchase Agreement”) with (i) Alesta Therapeutics B.V., a Dutch private limited liability company ( besloten vennootschap met beperkte aansprakelijkheid ) (the “Company” or “Alesta”) …Material agreement entered · Form 8-K
- Aug 6, 2026BioMarin Pharmaceutical Inc.Earnings release · press release
- Jul 13, 2026Report of Independent Registered Public Accounting Firm.Other event · press release
- Jun 4, 2026On June 2, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the Company) held its 2026 Annual Meeting of Stockholders (the Annual Meeting)Director or officer change · Form 8-K
- May 4, 2026BioMarin Pharmaceutical Inc.Earnings release · press release
- Apr 27, 2026The information set forth in.Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…